Drugmaker Lupin said on Wednesday it signed a licensing agreement with Sydney-based private speciality lifescience company NeuClone Pty Ltd for cell line technology.
"This agreement and such similar agreements, coupled with our own pipeline will go a long way in helping us address the impending opportunity and develop a substantial differentiated biological pipeline," President Cyrus Karkaria, said in the statement.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
